Meeting
2014 ASCO Annual Meeting
Pertuzumab (P) plus chemotherapy (CT) for platinum-resistant ovarian cancer: Safety run-in results of the PENELOPE trial.
Authors
Antonio Gonzalez-Martin
GEICO and Medical Oncology Service, Centro Oncológico M. D. Anderson International Spain, Madrid, Spain
Antonio Gonzalez-Martin , Patricia Pautier , Sven Mahner , Jörn Rau , Nicoletta Colombo , Petronella Ottevanger , Jose Maria Del Campo , Dominique Berton-Rigaud , Andreas Du Bois , Ulrich Freudensprung , Ru-Amir Walker , Christian Kurzeder
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT01684878
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 5552)
DOI
10.1200/jco.2014.32.15_suppl.5552
Abstract #
5552
Poster Bd #
334
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
PENELOPE/AGO-OVAR 2.20: A double-blind placebo (PLA)-controlled randomized phase III ENGOT trial evaluating chemotherapy (CT) with or without pertuzumab (P) for platinum-resistant ovarian cancer.
First Author: Christian Kurzeder
Poster
2019 ASCO Annual Meeting
Adavosertib with chemotherapy (CT) in patients (pts) with platinum-resistant ovarian cancer (PPROC): An open label, four-arm, phase II study.
First Author: Kathleen N. Moore
Poster
2019 ASCO Annual Meeting
Phase 2 trial of tisotumab vedotin in platinum-resistant ovarian cancer (innovaTV 208).
First Author: Haider Mahdi
Poster
2013 ASCO Annual Meeting
Health-related quality of life (HRQoL) results from the AURELIA trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum-resistant recurrent ovarian cancer (OC).
First Author: Martin R. Stockler